BRIEF-Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-In-Class Profile Of The Regimen Of Bemnifosbuvir And Ruzasvir For The Treatment Of Hepatitis C Virus At Easl Congress 2026

Atea Pharmaceuticals, Inc.

AVIR

0.00

May 27 (Reuters) - Atea Pharmaceuticals Inc AVIR.O:

ATEA PHARMACEUTICALS PRESENTS NEW DRUG-DRUG INTERACTION RESULTS SUPPORTING POTENTIAL BEST-IN-CLASS PROFILE OF THE REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR THE TREATMENT OF HEPATITIS C VIRUS AT EASL CONGRESS 2026
ATEA PHARMACEUTICALS INC - PHASE 1 STUDY SHOWS BEM/RZR SAFE AND WELL-TOLERATED WITH OR WITHOUT OMEPRAZOLE
ATEA PHARMACEUTICALS INC - OMEPRAZOLE AT 20 MG DOES NOT AFFECT BEM/RZR PLASMA EXPOSURE; 40 MG SLIGHTLY REDUCES EXPOSURE

Source text: ID:nGNX7dJ8NX

Further company coverage: AVIR.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.